Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AAV2-BDNF | MCI due to AD (Phase 1), Alzheimer's Disease (Phase 1) | Other | DNA/RNA-based | |||
| ABBV-552 | Alzheimer's Disease (Phase 1) | AbbVie | Other | Small Molecule | ||
| ACD856 | Alzheimer's Disease (Phase 1) | AlzeCure Pharma AB | Other | Small Molecule | ||
| AL101 | GSK-4527226 | Alzheimer's Disease (Phase 1) | Alector | Other | Immunotherapy (passive) | |
| BIIB118 | PF-05251749 | Alzheimer's Disease (Phase 1), Parkinson's Disease (Phase 1) | Biogen | Other | Small Molecule | |
| Empagliflozin | Jardiance, BI-10773 |
Alzheimer's Disease (Phase 1) | Boehringer Ingelheim, Eli Lilly & Co. | Other | Small Molecule | Type 2 Diabetes, Cardiovascular disease |
| Emtricitabine | Alzheimer's Disease (Phase 1) | Gilead Sciences, Inc. | Other | Small Molecule | ||
| Focused Ultrasound – Blood-Brain Barrier | FUS-BBB, MRgFUS, MRI-Guided Focused Ultrasound, FUS+MB |
Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 1), Mild Cognitive Impairment (Phase 1), Parkinson's Disease (Phase 1) | Amyloid-Related, Other | Procedural Intervention | ||
| IBC-Ab002 | Alzheimer's Disease (Phase 1) | ImmunoBrain Checkpoint | Amyloid-Related, Inflammation, Other | Immunotherapy (passive) | ||
| MemorEM Transcranial Electromagnetic Treatment | TEMT | Alzheimer's Disease (Phase 1) | NeuroEM Therapeutics, Inc. | Amyloid-Related, Other | Procedural Intervention | |
| NTRX-07 | MDA7 | Alzheimer's Disease (Phase 1) | NeuroTherapia, Inc. | Inflammation, Other | Small Molecule | |
| S-Equol | Aus-131 | Alzheimer's Disease (Phase 1) | Ausio Pharmaceuticals, LLC | Other | Small Molecule |